IL6R and congenital rubella syndrome: Starting from this data tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis,[1,2] systemic, giant cell arteritis,[3] and Cytokine Release Syndrome (CRS) occurring during therapy with Car-T,[4,5] has been proposed as a potentially effective drug in severe forms of COVID-19 pneumonia.[6] Similarly, sarilumab is a human monoclonal which binds specifically to IL6 (IL-6Rα) receptors both soluble and bound to the membrane and inhibits IL6 mediated signaling.